Based on sales of its Posicam PET systems during the past nine months, Positron of Houston has announced record earnings. Growth in the modality has helped fuel Positron's recovery.The company reported third quarter (ended Sept. 30) revenue of $3.4
Based on sales of its Posicam PET systems during the past nine months, Positron of Houston has announced record earnings. Growth in the modality has helped fuel Positron's recovery.
The company reported third quarter (ended Sept. 30) revenue of $3.4 million, compared with $385,000 for the same period a year ago. In addition, Positron had a $1.1 million profit for the first nine months, compared with $108,000 for the same period in 1999.
Positron was plucked from the financial brink a year and a half ago by EBCT manufacturer Imatron (SCAN, 5/13/98). That company saw an opportunity in Japan, where hospitals were developing cardiac scanning facilities that would employ both PET and ultrafast CT. As Imatron gained majority ownership of Positron, Imatron CFO Gary Brooks took over as Positron's CEO.
Imatron has divested most of its Positron shares, and now owns 16% of its stock, Brooks said. Imatron CEO Lewis Meyer remains Positron's board chairman.
"We're gearing up and settling some obligations from years past," said Mike Golden, Positron's controller. "We're looking for incremental growth."
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.